Abstract
Intra-uterine growth retardation (IUGR) represents one of the major problems in perinatal medicine. IUGR is one of main causes of perinatal mortality and morbidity. A huge number and variety of established and possible causes of IUGR have been described. There are currently no data about effective treatment of this fetal condition. IUGR has been described to be strictly involved in fetal programming. Fetal programming is the general idea, which tells us how during development of the embryo and fetus significant physiological parameters can be shaped by environmental events. A link between the intra-uterine growth retardation and the risk of developing type 2 diabetes, obesity and cardiovascular disease postnatally has been well documented. The aim of this paper is to present an overview of the current knowledge of IUGR effects on development of hypertension and cardiovascular diseases, impact on insulin secretion and resistance, diabetes mellitus and metabolic syndrome. The influence of intrauterine growth retardation on predisposition to obesity and adipose dysfunction was also described.
Keywords: Intra-uterine growth retardation, fetal programming, cardiovascular diseases, insulin secretion, insulin resistance, metabolic syndrome.
Current Pharmaceutical Biotechnology
Title:Intra-uterine Growth Retardation as a Risk Factor of Postnatal Metabolic Disorders
Volume: 17 Issue: 7
Author(s): Radzislaw Mierzynski, Dominik Dluski, Dorota Darmochwal-Kolarz, Elzbieta Poniedziałek-Czajkowska, Bozena Leszczynska-Gorzelak, Zaneta Kimber-Trojnar, Agnieszka-Wankowicz and Jan Oleszczuk
Affiliation:
Keywords: Intra-uterine growth retardation, fetal programming, cardiovascular diseases, insulin secretion, insulin resistance, metabolic syndrome.
Abstract: Intra-uterine growth retardation (IUGR) represents one of the major problems in perinatal medicine. IUGR is one of main causes of perinatal mortality and morbidity. A huge number and variety of established and possible causes of IUGR have been described. There are currently no data about effective treatment of this fetal condition. IUGR has been described to be strictly involved in fetal programming. Fetal programming is the general idea, which tells us how during development of the embryo and fetus significant physiological parameters can be shaped by environmental events. A link between the intra-uterine growth retardation and the risk of developing type 2 diabetes, obesity and cardiovascular disease postnatally has been well documented. The aim of this paper is to present an overview of the current knowledge of IUGR effects on development of hypertension and cardiovascular diseases, impact on insulin secretion and resistance, diabetes mellitus and metabolic syndrome. The influence of intrauterine growth retardation on predisposition to obesity and adipose dysfunction was also described.
Export Options
About this article
Cite this article as:
Mierzynski Radzislaw, Dluski Dominik, Darmochwal-Kolarz Dorota, Poniedziałek-Czajkowska Elzbieta, Leszczynska-Gorzelak Bozena, Kimber-Trojnar Zaneta, Agnieszka-Wankowicz and Oleszczuk Jan, Intra-uterine Growth Retardation as a Risk Factor of Postnatal Metabolic Disorders, Current Pharmaceutical Biotechnology 2016; 17 (7) . https://dx.doi.org/10.2174/1389201017666160301104323
DOI https://dx.doi.org/10.2174/1389201017666160301104323 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Parkinson's Disease, Diabetes and Cognitive Impairment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) From Pharmacotherapy to Pathophysiology: Emerging Mechanisms of Apolipoprotein D in Psychiatric Disorders
Current Molecular Medicine Novel Strategies for Preventing Diabetes and Obesity Complications with Natural Polyphenols
Current Medicinal Chemistry Genetics and Genomics Interventions for Promoting Millets as Functional Foods
Current Genomics HDL as a Target for Glycemic Control
Current Drug Targets Patent Perspective for Potential Antioxidant Compounds-Rutin and Quercetin
Recent Patents on Nanomedicine A Critical and Comprehensive Insight on Heme Oxygenase and Related Products Including Carbon Monoxide, Bilirubin, Biliverdin and Ferritin in Type-1 and Type-2 Diabetes
Current Pharmaceutical Design Current Perspectives of Healthy Mitochondrial Function for Healthy Neurons
Current Drug Targets Protein Modification by β-N-Acetyl Glucosamine (O-GlcNAc) in Insulin Signaling and Insulin Resistance
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Early Vascular Ageing (EVA): Definitions and Clinical Applicability
Current Hypertension Reviews Editorial (Hot Topic: Synthetic, Natural and Related Compounds: New Approach to Chronic Diseases Studies)
Current Topics in Medicinal Chemistry Cheminformatics Based Machine Learning Approaches for Assessing Glycolytic Pathway Antagonists of Mycobacterium tuberculosis
Combinatorial Chemistry & High Throughput Screening Targets for the Treatment of Erectile Dysfunction: Is NO/cGMP Still the Answer?
Recent Patents on Cardiovascular Drug Discovery Ghrelin as a Potential Anti-Obesity Target
Current Pharmaceutical Design The Role of Omega-3 Polyunsaturated Fatty Acids Supplementation in Childhood: A Review
Recent Patents on Cardiovascular Drug Discovery Orexins: Relation Between Sleeping, Eating, and Breathing
Current Respiratory Medicine Reviews Late versus Early Onset Depression in Elderly Patients: Vascular Risk and Cognitive Impairment
Current Aging Science History, Prevalence and Assessment of Limited Joint Mobility, from Stiff Hand Syndrome to Diabetic Foot Ulcer Prevention: A Narrative Review of the Literature
Current Diabetes Reviews Charcot Neuroarthropathy: From the Laboratory to the Bedside
Current Diabetes Reviews Role of Endogenous GLP-1 and its Agonists in Osteopenia and Osteoporosis: But We Little Know Until Tried
Current Diabetes Reviews